title: [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
abstract: Alteration of the p53 gene product occurs frequently during the progression of colorectal cancer. Recently, mutated p53 protein was found to induce the production of anti-p53 antibodies in the serum of patients. The purpose of this study was to evaluate the relationship between p53 status in serum and chemosensitivity in resectable colorectal cancer patients. A total of 35 patients with primary colorectal cancer who underwent surgical treatment were examined by chemosensitivity test with the viable tumor samples using Histoculture Drug Response Assay (HDRA). Serum samples of these patients to test for p53 antibodies were obtained before tumor resection, and assayed in duplicate by using an enzyme-linked immunosorbent assay (ELISA) kit. The inhibition index of 5-FU and CDDP, determined by the HDRA method, in the sero-positive group was significantly lower than that of the sero-negative group (p < 0.01). Furthermore, significant statistical differences in chemosensitivity to 5-FU and CDDP were revealed depending on the presence of serum p53 antibodies. There was no relationship between chemosensitivity assay and tumor marker positivity or clinicopathological features in these patients. Detection of serum p53 antibodies, which reflects p53 mutations in tumor tissue, is a simple method which correlates with chemosensitivity, and may contribute to the selection of favorable chemotherapeutic strategies of colorectal cancer.
authors.affiliation: Second Dept. of Surgery, School of Medicine, Chiba University.
authors.forename: A
authors.initials: A
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: K
authors.initials: K
authors.lastname: Nakajima
authors.forename: H
authors.initials: H
authors.lastname: Imaseki
authors.forename: S
authors.initials: S
authors.lastname: Okazumi
authors.forename: W
authors.initials: W
authors.lastname: Takayama
authors.forename: K
authors.initials: K
authors.lastname: Iwasaki
authors.forename: H
authors.initials: H
authors.lastname: Makino
authors.forename: T
authors.initials: T
authors.lastname: Natsume
authors.forename: T
authors.initials: T
authors.lastname: Kouno
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Ochiai
authors.forename: K
authors.initials: K
authors.lastname: Isono
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001323:Autoantibodies / Q000097:blood*; D002945:Cisplatin / Q000494:pharmacology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000473:pathology; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents; D001323:Autoantibodies; D016159:Tumor Suppressor Protein p53; D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil